P

Pfizer

Makes cancer drugs, vaccines and other medicines

Vice President - Digital Finance

Full-TimePosted on 10/19/2026Deadline 10/27/26
$274k - $456.6k/yr+ 30% target bonus + Share-based long-term incentive program
Expert
Bachelor's, Master's
New York, NY, USA
HybridHybrid role; travel up to 20% of the time, including on-site working sessions and executive reviews.
IT OperationsIT Project Management, Enterprise Applications
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in business, finance, engineering, computer science, or a related field, plus 15 years of experience.
  • At least 10 years of experience in digital finance leadership roles spanning financial planning and analysis, planning, budgeting and forecasting, consolidation and close, and finance platform delivery.
  • Experience leading an enterprise-scale planning, budgeting and forecasting transformation from design through global release and adoption, ideally AI-driven.
  • Strong knowledge of finance processes and platforms, including Oracle Enterprise Performance Management (EPM) Planning, Financial Consolidation and Close Cloud Service (FCCS), Enterprise Data Management, SAP finance, cloud data platforms, gross-to-net, and controllership processes.
  • A track record of delivering artificial intelligence and generative artificial intelligence capabilities at scale with measurable, audited business value, including predictive forecasting and forecast-accuracy measurement.
  • Experience operating in Sarbanes-Oxley-controlled environments, including audit readiness, information technology general controls, and model governance.
  • Leadership, communication, and program management skills, including the ability to influence executive vice president- and senior vice president-level leaders.
  • Experience directing system integrators and strategic vendors on large, multi-workstream programs.
  • Experience leading global, multi-country teams of colleagues and contracted resources.
  • Ability to work in a fast-paced environment and manage multiple priorities, including running the platforms while delivering the planning, budgeting and forecasting program.
  • Strong analytical skills and the ability to interpret data to drive decision-making.
  • Candidates must be authorized to be employed in the United States by any employer and must have permanent work authorization in the United States.
Responsibilities
  • Lead Pfizer’s global Digital Finance Creation Center and deliver the enterprise Planning, Budgeting & Forecasting transformation, replacing the bottom-up forecasting process with an artificial-intelligence-native, unbiased, explainable profit-and-loss forecast.
  • Own end-to-end delivery of the forecast, including scope, plan, budget, risks, releases, and updates to the executive ATC forum in partnership with the enterprise program office.
  • Hold the program accountable for forecast accuracy against actuals, shorter forecast cycles, and adoption of review by exception; make release and go-live decisions based on back-tested accuracy, with confidence indicators and traceable sources for every number.
  • Serve as the Digital executive partner to senior vice president and executive vice president leaders across Finance, Commercial, Global Product Supply, Research and Development, and Digital; lead executive steering updates, resolve cross-functional trade-offs, and secure sponsorship for adoption of a single trusted forecast baseline.
  • Define the target technology architecture across planning, consolidation, close, and SAP finance actuals reporting; evaluate platforms based on return on investment, fit, delivery risk, and total cost of ownership; prioritize and scale artificial intelligence and agentic use cases in Finance with value tracking and adoption measures.
  • Maintain Sarbanes-Oxley compliance and audit readiness across Finance platforms and establish decision rights, model monitoring, and controls for artificial-intelligence-generated forecasts.
  • Ensure the stability, performance, continuous improvement, and dependable support of Oracle EPM, gross-to-net, Global Financial Planning and Analysis, consolidation, close, external reporting, controllership, and Tax and Treasury solutions, including during quarter-end and year-end close.
  • Support environmental, social, and governance and Finance support requirements for mergers and acquisitions activity.
  • Unify actuals, budget, forecast, pricing and gross-to-net, supply, and commercial data into a governed, reconciled, and secure foundation shared by Planning, Budgeting & Forecasting and Global Financial Planning and Analysis; ensure financial and unit forecasts are aligned.
  • Direct system integrators and strategic partners across program management, design, infrastructure, data modeling, and support, with discipline on scope, resourcing, and value.
  • Manage Digital Finance capital and operating budgets and the program’s one-time and run costs against the approved business case.
  • Lead senior directors and their teams across multiple countries, along with matrixed workstream leads and contracted resources; create a single point of contact for Finance partners, build succession depth, and foster innovation, accountability, and continuous learning.
Desired Qualifications
  • A master's degree in business administration or a related field, plus 13 years of experience.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.